Resources

In sub-Saharan Africa, malaria in pregnancy continues to contribute to high maternal and newborn morbidity and mortality. One approach to the problem is intermittent preventive treatment of malaria in pregnancy with sulfadoxine pyrimethamine, an antimalarial safe for use in pregnancy. This report reviews recent studies and articles documenting implementation of community-based approaches that increase uptake of this therapy. See also Community-Based Approach to Intermittent Treatment for Malaria in Pregnancy in Kisumu, Kenya: Exploring the Value of Utilizing Community Health Workers in Malaria in Pregnancy Prevention.

This e-book, written by the Digital Health Solutions team for the Joint Learning Network for Universal Health Coverage, is a reference guide for countries wanting to link their universal health coverage and eHealth information systems using a standards-based approach. It provides a set of actionable steps and links to resources to develop a national eHealth standards framework. The e-book can be read online, downloaded as a PDF, or downloaded to an e-reader.

This publication features articles from global leaders in innovation exploring the critical role innovation can play in accelerating solutions to the world’s most urgent health challenges.

An expert advisory group meeting was held at PATH in August 2014 to build consensus among knowledge leaders and active researchers on approaches to improve oxygen concentrators to treat pediatric patients with hypoxemia or severe respiratory distress in low-resource settings. Key issues including procurement, performance, and maintenance were identified.

An Ov16 positive control has been developed: a recombinant, monoclonal human IgG4 antibody to Ov16.Two ELISA methods for anti-Ov16 human IgG4 were assessed using the Ov16 positive control.HRP-based ELISA results in a lower limit of detection and superior detection of clinical pool and control positives as compared to AP-based ELISA.Dried blood spots are an acceptable specimen type with both ELISA methods.The anti-Ov16 antibody has been further developed as a quality control and quality assurance reagent for:ELISA standardization and quality controlManufacturing control of Ov16 RDTField-stable RDT control to support training and as quality assurance reagent for RDTs at different points of the supply chain from manufacturer to use.